股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國匯融金融控股有限公司 呈交日期: 2025年12月4日 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,00 ...

Core Viewpoint - The article discusses the concept of stock pledge financing as a flexible tool for major shareholders of listed companies to access liquidity without selling their shares, thus maintaining their control over the company [1][7]. Group 1: Stock Pledge Financing Overview - Stock pledge financing allows major shareholders to use their shares as collateral to obtain funds from financial institutions, addressing immediate financial needs while preserving ownership [4][7]. - This method is likened to pawning a valuable item, where the shareholder retains the asset but risks losing it if they fail to repay the loan [4][9]. Group 2: Benefits of Stock Pledge Financing - It provides liquidity to shareholders without losing their shareholder status, enabling them to fund operations, investments, or mergers [10]. - Unlike direct stock sales, stock pledge financing does not immediately impact market perception or stock prices, helping to stabilize market confidence [11]. - The process is efficient and flexible, often featuring lower interest rates compared to traditional loans, thus quickly meeting funding needs [12]. Group 3: Stock Pledge Financing Process - The standard process begins with discussions and due diligence, where financial institutions assess the shareholder's qualifications, the purpose of the funds, and the quality of the pledged stock [13]. - Key terms such as financing scale, duration, interest rate, and pledge ratio are established in the agreement, with specific risk control measures in place [15]. - Risk control includes a pledge ratio, warning line, and liquidation line to manage potential declines in stock value and protect the lender's interests [16][17]. Group 4: Risks and Considerations - While stock pledge financing can alleviate financial pressure and support business development, excessive pledge ratios or poor management can lead to risks such as forced liquidation and control disputes [17].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國匯融金融控股有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 呈交日期: 2025年10月8日 公司名稱: 中國匯融金融控股有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | ...

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][10] Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [3][4] - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [9] - A exclusivity period is set from the signing date until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [9] Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [11][13] - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [11][13] Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [15] - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% year-on-year to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [18][19]

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [1][2]. Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [2]. - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [7]. - A exclusivity period is established from the signing date until May 31, 2026, during which the sellers cannot negotiate with other parties regarding the equity transfer [7]. Group 2: Strategic Intent - The acquisition is part of Dongxing Medical's strategic need for business development and aims to extend its surgical medical device industry chain while actively expanding into the synthetic biology field [8]. - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [8][10]. Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on the Shenzhen Stock Exchange on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [11]. - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [13][14].

Group 1 - The core point of the article is that Dongxing Medical announced the acquisition of 90% of Wuhan Yijiaobao's shares, which will make it a subsidiary if the transaction is successfully completed [1][4]. - Dongxing Medical aims to expand its synthetic biology business segment through this acquisition, as part of its strategic business development [4]. - Wuhan Yijiaobao is identified as a high-tech enterprise focused on the research, production, and sales of advanced orthopedic and biomedical materials [4]. Group 2 - As of September 26, Dongxing Medical's stock price was 27.96 yuan per share, with a market capitalization of approximately 2.8 billion yuan [5]. - The ownership structure of Wuhan Yijiaobao is straightforward, with only two shareholders involved [5]. - Dongxing Medical has around 10,400 shareholders as of September this year [5].

CHINA HUIRONG FINANCIAL HOLDINGS LIMITED 中國匯融金融控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1290） 各位非登記股東1 ： 於本公司網站登載公司通訊之通知 謹此通知 閣下，中國匯融金融控股有限公司（「本公司」）之下述公司通訊（「2 本次公司通訊」）之中、英文 版本，現已登載於本公司網站www.cnhuirong.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」） 網站www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若 閣下早前曾要求收取公司通 訊的印刷本，本次公司通訊的印刷本已隨函附上。 1. 非登記股東指將所持有之本公司股份存放於中央結算系統的人士或公司。 2. 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件，其中包括 但不限於(a)董事會報告，公司年度帳目連同核數師報告以及（如適用）財務摘要報告；(b)中期報告及（如適用）中 期摘要報告；(c)季度報告（如有）；(d)會議通告；(e)上市文件；( ...

CHINA HUIRONG FINANCIAL HOLDINGS LIMITED 中國匯融金融控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1290） 各位註冊股東： 於本公司網站登載公司通訊之通知 謹此通知 閣下，中國匯融金融控股有限公司（「本公司」）之下述公司通訊（「1 本次公司通訊」）之中、英文 版本，現已登載於本公司網站www.cnhuirong.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」） 網站www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若 閣下早前曾要求收取公司通 訊的印刷本，本次公司通訊的印刷本已隨函附上。 為了支援通過電郵進行電子通訊，本公司建議 閣下向本公司香港股份過戶登記分處卓佳證券登記有限 公司（「香港股份過戶登記分處」）（地址為香港夏慤道16號遠東金融中心17樓）發出（不少於7天的）合理書 面通知，或發送電郵至1290-ecom@vistra.com向本公司提供 閣下的電郵地址。 股東有責任提供有效的電郵地址。若 閣下沒有提供有效的電郵地址，本公司將透過 ...

Financial Performance - Operating revenue for the six months ended June 30, 2025, was RMB 345,814,000, a decrease of 2% compared to RMB 351,380,000 in 2024[13] - Profit attributable to equity holders of the company increased by 7% to RMB 32,762,000 from RMB 30,609,000 in the previous year[13] - Total assets decreased by 5% to RMB 3,319,707,000 from RMB 3,504,127,000[13] - Total liabilities decreased by 14% to RMB 1,118,343,000 from RMB 1,301,438,000[13] - The company reported an 11% increase in bank deposits and cash on hand, totaling RMB 164,877,000[13] - The company’s basic earnings per share rose by 7% to RMB 0.030 from RMB 0.028 in the previous year[13] - Total new loans issued in the first half of 2025 amounted to RMB 151 million, a decrease of 64.7% compared to RMB 427 million in 2024[28] - Interest income for the period was RMB 22,144 thousand, representing a decline from RMB 24,499 thousand in the previous year[28] - The company reported a pre-tax profit of RMB 14,592 thousand for the six months ended June 30, 2025, compared to a loss of RMB 13,310 thousand in the previous year, indicating a significant turnaround[74] Business Strategy and Development - The company focused on optimizing its business structure and enhancing risk control amid a challenging economic environment[15] - The company aims to become a leading provider of inclusive financial services in China, leveraging platforms like Wu Zhong Pawn and Dongshan Microfinance[16] - The company is committed to a strategy of innovation-driven development to address challenges in the financial sector[15] - Future development strategies include focusing on quality and adjusting operational strategies to enhance market competitiveness[22] - The company aims to expand its non-mortgage loan business by increasing the scale of listed company stock pledge loans[26] - The company plans to focus on providing liquidity support for large, stable assets and strengthen cooperation with state-owned small loan institutions[32] - The company aims to support the transfer loan needs of small and medium-sized enterprises while adhering to regulatory requirements[36] - The company plans to focus on advanced manufacturing, healthcare, and public utilities for future development in the leasing business[53] - The company continues to seek new business development opportunities and plans to fund investments through its own resources and bank financing[177] Loan and Mortgage Performance - Total new real estate mortgage loans issued in the first half of 2025 was 91, a decrease of 62% compared to 243 in the same period of 2024[18] - Total new movable property mortgage loans issued was 499, down 50% from 1,001 in the previous year[18] - The outstanding balance of real estate mortgage loans as of June 30, 2025, was RMB 683 million, a decrease from RMB 793 million year-on-year[21] - Interest income from real estate mortgage loans was RMB 16,596 thousand, a decline compared to RMB 54,830 thousand in the same period last year[21] - The outstanding balance of non-mortgage loans was RMB 482 million, an increase from RMB 436 million year-on-year[25] - Interest income from non-mortgage loans rose to RMB 44,310 thousand, up from RMB 10,175 thousand in the previous year[25] - The outstanding balance of mortgage loans was RMB 299 million, with 62 total customers, of which 53 were individual clients[29] - The outstanding balance of guarantee loans was RMB 71 million, with 23 total customers, of which 12 were individual clients[31] - The outstanding balance of credit loans was RMB 125 million, with 9 total customers, of which 1 was an individual client[31] Risk Management and Credit Quality - The company has implemented comprehensive internal control measures to manage risks associated with its pawn business[27] - The expected credit loss provision for loans granted to customers totaled RMB 652,373 thousand as of June 30, 2025, representing approximately 21.55% of the total loans granted before provisions[82] - The expected credit loss provision decreased by RMB 173,380 thousand compared to the end of the previous year, reflecting improved credit quality[82] - The group has established clear guidelines and policies for credit risk assessment and management across its lending business units, including pawn, small loans, and overseas finance[87] - The group conducts thorough due diligence and credit assessments before granting loans, ensuring compliance with internal guidelines[89] - The company emphasizes the importance of asset quality and has increased efforts in risk management and recovery processes[84] - The company monitors loan repayments closely, implementing response plans for overdue payments based on the operational status and repayment willingness of the clients[124] Investment and Asset Management - The total book value of loans granted to customers was RMB 3,027,416 thousand, with a breakdown of RMB 1,622,810 thousand for collateralized loans and RMB 1,404,606 thousand for non-collateralized loans[77] - The total book value of financial assets held under repurchase agreements was RMB 221,390 thousand, with an expected credit loss provision of RMB 3,527 thousand[78] - The total investment amount in special asset investment business reached RMB 306 million, with no new investments made during the period[62] - Interest income for the special asset investment business was RMB 3,351 thousand, a significant decrease from RMB 16,524 thousand in the previous year due to the absence of new investment projects[62] - The company’s strategy includes actively seeking financing solutions in the areas of restructuring and auction financing for clients[164] Operational Efficiency and Cost Management - The company plans to continue promoting refined management to achieve cost reduction and efficiency improvement in the future[74] - The company is focusing on investment management, risk control, technology support, and logistics services to enhance operational efficiency[74] - The company has implemented a comprehensive risk management system covering all employees, products, and processes[146] - The company will only disburse funds after ensuring all loan approvals, contract signings, and guarantee measures are completed[142] Shareholder and Equity Information - As of June 30, 2025, the company had a total of 1,090,335,000 issued shares, with significant shareholders holding over 5% of the shares, including Xiaolai Investment Co., Ltd. with 23.85%[188] - The board of directors and senior management hold a total of 4,730,000 shares, representing 0.43% of the issued shares[185] - The total number of shares available for issuance under the stock option plan is capped at 10% of the total shares issued as of the adoption date, amounting to 102,523,700 shares[197] - The overall limit for shares that may be issued upon the exercise of all outstanding stock options under the stock option plan and any other plans is capped at 30% of the company's issued shares[198] - No eligible person may be granted stock options that would result in their total shares exceeding 1% of the issued shares within a 12-month period without shareholder approval[199] Cash Flow and Financial Position - As of June 30, 2025, the company's cash and cash equivalents amounted to RMB 89,497,000, a decrease of RMB 46,574,000 compared to the previous year[170] - Net cash inflow from operating activities for the six months ended June 30, 2025, was RMB 261,485,000, primarily due to a reduction in loans granted to customers[171] - Net cash outflow from investing activities for the same period was RMB 108,449,000, mainly due to payments for potential project deposits[172] - Net cash outflow from financing activities was RMB 199,312,000, attributed to increased loan repayments alongside a decrease in new borrowings[173]